Allogene Therapeutics, Inc.

8-K Shareholder vote results; Other events Jun 22, 2026 8-K Director or officer change May 28, 2026 10-Q Quarter ended 2026-03-31 May 13, 2026 8-K Entered a material agreement; Terminated a material agreement; Results of operations (earnings release) May 13, 2026 8-K Other events Apr 15, 2026 8-K Other events Apr 13, 2026 8-K Other events Apr 13, 2026 10-K Fiscal year ended 2025-12-31 Mar 12, 2026 8-K Results of operations (earnings release) Mar 12, 2026 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Results of operations (earnings release) Nov 6, 2025 8-K Other events Oct 14, 2025 10-Q Quarter ended 2025-06-30 Aug 13, 2025 8-K Results of operations (earnings release) Aug 13, 2025 8-K Other events Aug 1, 2025 8-K Shareholder vote results Jun 23, 2025 10-Q Quarter ended 2025-03-31 May 13, 2025 8-K Results of operations (earnings release) May 13, 2025 10-K Fiscal year ended 2024-12-31 Mar 13, 2025 8-K Results of operations (earnings release) Mar 13, 2025 8-K Entered a material agreement Feb 25, 2025 8-K Director or officer change Jan 29, 2025 8-K Other events Nov 13, 2024 10-Q Quarter ended 2024-09-30 Nov 7, 2024 8-K Results of operations (earnings release) Nov 7, 2024 8-K Item 5.05 Oct 7, 2024 10-Q Quarter ended 2024-06-30 Aug 7, 2024 8-K Results of operations (earnings release) Aug 7, 2024 8-K Director or officer change; Shareholder vote results Jun 10, 2024 8-K Entered a material agreement May 31, 2024 8-K Other events May 14, 2024 10-Q Quarter ended 2024-03-31 May 13, 2024 8-K Results of operations (earnings release) May 13, 2024 10-K Fiscal year ended 2023-12-31 Mar 14, 2024 8-K Results of operations (earnings release) Mar 14, 2024 10-K/A Fiscal year ended 2022-12-31 Mar 14, 2024 8-K Previously issued financials not reliable Feb 16, 2024 8-K Entered a material agreement Jan 31, 2024 8-K Entered a material agreement; Exit or disposal costs; Other events Jan 5, 2024 8-K Other events Dec 19, 2023